SMTI
Sanara MedTech Inc. · NASDAQ
- Market cap
- $300.6M
Sanara MedTech Inc. (SMTI) is an Industrial Specialties company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for SMTI, including 4 SEC filings and 1 earnings update. The most recent was published Nov 12, 2026.
Financial highlights
Full financials- Revenue, TTM
- $111.91M
- Revenue growth
- +9.8%
- Net income, TTM
- -$3.02M
- Net margin
- -2.7%
- Free cash flow, TTM
- $7.29M
- Cash
- $16.79M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks39+67%
2026-05-242026-11-15
Mix1190d
- SEC Filings9(82%)
- Insider1(9%)
- Earnings1(9%)
Activity · 52 weeks7333 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Sanara MedTech Inc.10-Q - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sanara MedTech Inc. (0000714256) (Filer)
- PRSanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)FORT WORTH, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Summary(1) ●Net revenue increased 8% to $28.4 million, compared to $26.3 million in the third quarter of 2025. ●Gross profit of $26.3 million, or 93% of net revenue, compared to gross profit of $24.5 million, or 93% of net revenue, in the third
- SECSEC Form 8-K filed by Sanara MedTech Inc.8-K - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 8-K filed by Sanara MedTech Inc.8-K - Sanara MedTech Inc. (0000714256) (Filer)
- SECSanara MedTech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events8-K - Sanara MedTech Inc. (0000714256) (Filer)
- INSIDERChief Executive Officer Yon Seth D covered exercise/tax liability with 3,661 shares, decreasing direct ownership by 3% to 105,885 units (SEC Form 4) (tax withholding)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- SECSEC Form DEFM14A filed by Sanara MedTech Inc.DEFM14A - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 10-Q filed by Sanara MedTech Inc.10-Q - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sanara MedTech Inc. (0000714256) (Filer)
- PRSanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Summary(1) ●Net revenue increased 9% to $28.1 million, compared to $25.8 million in the second quarter of 2025. ●Gross profit of $26.2 million, or 93% of net revenue, compared to gross profit of $23.9 million, or 92% of net revenue, in the second q
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECAmendment: Sanara MedTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K/A - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- ANALYSTSanara MedTech downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Sanara MedTech from Buy to Neutral and set a new price target of $35.00
SMTI FAQ
10 questionsWhat does Sanara MedTech Inc. do?
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes...What is the latest news on SMTI?
In the last 30 days Quantisnow tracked 5 wire items for SMTI: 4 SEC filings and 1 earnings update. The most recent was published on November 12, 2026.What is SMTI revenue?
Sanara MedTech Inc. (SMTI) reported $111.91M of revenue for the twelve months ended Sep 30, 2026. That is up 9.8% from the year before. Revenue for fiscal 2025 was $103.12M.Is SMTI profitable?
No. Sanara MedTech Inc. reported a net loss of $3.02M for the twelve months ended Sep 30, 2026.How much cash and debt does SMTI have?
Sanara MedTech Inc. reported $16.79M in cash and cash equivalents and $46.72M of debt on its most recent balance sheet in SEC filings.Where does SMTI stock trade?
Sanara MedTech Inc. (SMTI) is listed on NASDAQ.What sector and industry is SMTI in?
Sanara MedTech Inc. operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about SMTI?
Across the last 6 analyst actions on Sanara MedTech Inc., there were 0 upgrades and 1 downgrade. The most recent action was from H.C. Wainwright: Neutral with a $35.00 price target on 2026-07-30. Recent price targets range from $32.00 to $51.00.What companies are similar to SMTI?
Notable peers in the same industry include ZBH (Zimmer Biomet Holdings Inc.), STE (STERIS plc (Ireland)), ALGN (Align Technology Inc.), EW (Edwards Lifesciences Corporation), ISRG (Intuitive Surgical Inc.). Compare SMTI side-by-side with any of them on Quantisnow.How can I track SMTI on Quantisnow?
Quantisnow aggregates Sanara MedTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SMTI to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change